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A B S T R A C T
Polyphenols and n-3 polyunsaturated fatty acids (PUFAs) are two classes of natural compounds, which
have been highlighted in epidemiological studies for their health beneﬁts. The biological activities of those
two families of metabolites on oxidation, inﬂammation, cancer, cardiovascular and degenerative dis-
eases have been reported in vitro and in vivo. On the other hand, chemical bonding between the two
structures leading to n-3 lipophenol derivatives (or phenolipids) has been studied in numerous works
over the last decade, and some examples could also be found from natural sources. Interest in lipophilization
of phenolic structures is various and depends on the domain of interest: in food industry, the develop-
ment of lipidic antioxidants could be performed to protect lipidic food matrix from oxidation. Whereas,
on pharmaceutical purpose, increasing the lipophilicity of polar phenolic drugs could be performed to
improve their pharmacological proﬁle. Moreover, combining both therapeutic aspects of n-3 PUFAs and
of polyphenols in a single lipophenolic molecule could also be envisaged. An overview of the synthesis
and of the natural sources of n-3 lipophenols is presented here, in addition to their biological activities
which point out in several cases the beneﬁt of the conjugated derivatives.
© 2015 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights
reserved.
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1. Introduction
Health beneﬁts of polyunsaturated fatty acids of the omega-3
family have been largely reported in the last decades [1,2]. The most
common ones are α-linolenic acid (C18:3, ALA), eicosapentaenoic
acid (C20:5, EPA) and docosahexaenoic acid (C22:6, DHA). They are
reported as “essential fatty acids”, seem to be involved in the re-
duction of inﬂammation andmay help lower risk of chronic diseases
such as heart disease, cancer, and arthritis. As they are highly con-
centrated in the brain, they are also implicated in cognitive and
behavioral functions [3]. Several omega-3-polyunsaturated fatty acid
(n-3 PUFA) conjugates have been developed in recent literature to
improve the eﬃciency of active molecules. Among them, this review
will focus especially on PUFA-Phenol conjugates, including inter alia,
ﬂavonoid, catechol, phloroglucinol derivatives, already known for
their therapeutic applications (anti-oxidative, anti-inﬂammatory, an-
ticancer activities . . .) [4], as well as natural omega-3 lipophenols.
The rational to design lipophenol derivatives depends either on
the initial phenolic drug or on the targeted pathology: linkage of
highly hydrophilic drugs to n-3 PUFA may help to increase
lipophilicity, cell penetration and bioavailability of speciﬁc polar phe-
nolic drugs. On the contrary, conjugation with PUFA would be
interesting to reach appropriate solubility of hydrophobic drugs, by
facilitating its binding to human serum albumin (HSA) [5,6]. In some
cases, PUFA conjugates have been investigated to target speciﬁc
tissues, either ones rich in n-3 PUFA such as retina or brain (high
content in DHA and EPA) [3,7], or tumor tissues in which PUFA
uptake is particularly high. On one side, since PUFAs are prime targets
for oxidation (due to numerous bis-allylic positions) [8], linkage with
antioxidant such as phenolic compounds would also help to limit
auto-oxidation, to prevent the resulting harmful effects of lipid ox-
idation and to preserve health beneﬁts of PUFA. On the other side,
esteriﬁcation of phenolic drugs by PUFA is a good way to mask their
hydroxyl polar functions and thus, to reduce their biotransforma-
tion or the pace of oxidative degradation. In addition, conjugation
with a PUFA part may contribute to increase antioxidant proper-
ties of phenolic compounds in lipophilic media. Depending on the
pathology studied, synergism effect between the phenolic and the
PUFA parts could be expected. In those cases PUFA would be able
to enhance the eﬃcacy of the phenolic drug, not only by the release
of the drug but by the combined functionality of both moieties of
the conjugate (including their metabolites).
For all those reasons several research teams worked on the syn-
thesis and the evaluation of a wide range of lipophenols, however,
natural sources offer also the possibility to access lipophenol struc-
tures. As an example, several lipophenols bearing a n-3 PUFA part
and a phloroglucinol moiety have been identiﬁed, mainly in veg-
etable sources [9]. Interest in natural n-3 lipophenols resides in their
diverse biological activities.
As an illustration, we describe herein the main synthetic strat-
egies to access n-3 lipophenols, the source and/or the total synthesis
of natural n-3 lipophenolic derivatives, and we will discuss the
current and potential therapeutic applications of the resulting com-
pounds presented in the literature. Even though other n-3 PUFA
conjugates bearing phenolic residues have been described, this
review will focus speciﬁcally on bioactive compounds in which the
phenolic or polyphenolic moiety plays a major role in the biolog-
ical properties of the molecule.
2. The chemical or enzymatic pathway to access n-3
lipophenols
Introduction of PUFA on phenolic cores can be performed chem-
ically, enzymatically, or chemo enzymatically, most often through
esteriﬁcation/acylation of the phenolic-OH with fatty acids. Fig. 1
presents phenolic molecules that have been transformed into li-
pophilic derivatives using n-3 PUFAs, with position of the reported
acylation in red/pink color.
2.1. Enzymatic synthesis
The synthesis of n-3 PUFA-phenols depends on the structure of
the phenolic part. Indeed, different types of bioactive phenols have
been linked to ALA, EPA or DHA. Among them, are reported poly-
phenolic compounds belonging to the ﬂavonoids family such as rutin
5, phloridzin 6, isoquercitrin 7, naringin 4, quercetin 3 or
epigallocatechins 1–2 (Fig. 1). The enzymatic way, involving lipases,
most usually novozyme 435 (commercially immobilized lipase from
Candica antarctica – CALB), is always preferred to the chemical one
to introduce PUFA on heterosidic ﬂavonoids. Its high regioselectivity
allows introduction of only one fatty acid (FA) residue on the sugar
part, and mild reaction conditions avoid substrate alteration. The
most studied ﬂavonoid for this purpose was rutin (5).
Enzymatic esteriﬁcation using CALB is usually performed in
acetone [10–12], 2-methyl-2-butanol [13,14] or in a mixture of both
solvents [15], which were selected for their abilities to solubilize
both the reactant and the ﬁnal lipophenol, providing excellent ac-
tivity and stability of the lipase. The lipase allows the introduction
of ALA, EPA or DHA speciﬁcally at the 4‴-hydroxyl group of the
rhamnosyl moiety. Mbatia et al. [10] performed the reaction using
a mixture of PUFAs enriched in ALA, EPA and DHA, in proportion
phenol/FA 1/4 at 50 °C during 96 h. They reported 30% yield of the
3 lipophenols (5) without puriﬁcation. Using similar protocol with
pure ALA (phenol/FA 1/5, 50 °C, 96 h), Mellou et al. [11] observed
up to 68% of esteriﬁcation (measured by HPLC) while Viscupicova
et al. [13,14] obtained around 30% of conversion using the same PUFA
(phenol/FA:1/5, 60 °C, 168 h). Thoseworks pointed out that the yields
of enzymatic rutin esteriﬁcation, inversely correlates the chain length
of fatty acid (with C4–C12 fatty acids, yield >50%), probably due to
steric hindrance/constraints in the active site of the CALB. It has also
been reported that the presence of double bonds could negatively
inﬂuence the lipase speciﬁcity to a large extent. However this was
not clearly demonstrated with rutin.
More recently Zheng et al. [15], introduced ultrasound activa-
tion to link ALA to rutin (5) and naringin (4) in the presence of CALB
(wrong structure of naringin is reported by the authors). Microtip
probe ultrasonic pretreatment to esteriﬁcation of ﬂavonoids (fre-
quency 25 KHz, power 150–200 W), allowed to use lower PUFA’s
equivalents and reduced reaction time (48–72 h instead of 72–
96 h), compared to stirring experiments to reach up to 80% of
conversion without damaging the lipase. Ziaullah et al. [12] were
the only ones to perform phloridzin acylation at the 6″ position of
the glucose, with each of the three PUFAs ALA, EPA and DHA, using
the stirring process (acetone, 45°–50 °C, 12–24 h) and obtained re-
spectively 94, 85 and 82% yields after puriﬁcation of phloridzin-
ALA, -EPA and -DHA 6. The same work on isoquercitrin (7) led to
the acylation of the 6″-OH position of the sugar moiety with a com-
plete regioselectivity and 91, 81 and 81% yield, respectively. In
addition to the presence of ﬂame dried molecular sieves to remove
any in situ generated water in the reaction mixture, they focused
on the need to dry the enzyme over P2O5 for 20 h before the reac-
tion and to maintain extra dry condition so as to limit hydrolysis
and drag the reaction forward.
Lipase-catalyzed esteriﬁcation and transesteriﬁcation were used
to produce lipophenol structures having a catechol part like vanillyl
alcohol, dihydrocaffeic acid or hydroxytyrosol. Using the speciﬁc-
ity of CALB to acylate primary hydroxyl groups compared to
secondary hydroxyl ones, MBatia et al. [10] reported, as for rutin
but with an increased yield (60%), the synthesis of a mixture of ALA,
EPA and DHA vanillyl esters 10, using CALB in acetone. Addition-
ally, EPA and DHA were introduced in the olive oil hydroxytyrosol
(13) and in analogue structures through transesteriﬁcation, cata-
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lyzed by CALB under stirring and vacuum (5–10 mmHg, 37 °C,
4–16 h, 29–97%) [16]. In this work, important decreased yields were
observed, going from EPA and DHA ethyl esters to saturated ethyl
palmitate and stearate esters. Weak conversions were explained by
the partial hydrolysis of the PUFA ethyl esters during the reaction.
Finally, CALB was used to investigate the lipase transesteriﬁcation
reaction of dihydrocaffeic acid (DHCA) with ﬂaxseed oil (rich in ALA
and other C18 fatty acids glycerides), in order to obtain phenolic
mono or diacyl glycerol enriched in ALA (14). The high speciﬁcity
and stereoselectivity of the enzyme towards C18:1 n-9 and C18:2
n-6 for transesteriﬁcation reaction, led to an increased proportion
of ALA in the phenolic diacyl glycerol structure [17].
2.2. Chemical synthesis
The introduction of a PUFA moiety onto chemical structures
having a single free phenolic function (juglone 21, propofol 19, podo-
phyllotoxin derivatives 23), or one amino or aliphatic-alcohol group,
with higher nucleophilicity than the phenolic one (dopamine and
analogues 12, trimethoxy anilide 18, farinosone C 20, shikonin 22),
was performed either by the well-established esteriﬁcation proce-
dure using either the proper preformed mixed anhydrides [18,19]
or acyl chlorides [20–22] of the PUFA, or a classical coupling reagent,
such as, DCC/DMAP [23–27], pentaﬂuorophenol/TEA [28], TBTU/
TEA [29] or TCTU/TEA [30]. Whatever the used procedure and
reagents, moderate to good yields were obtained.
For more complex polyphenolic structures like epigallocatechine-
3-O-gallate (EGCG) 1 [31–33], epigallocatechin (EGC) 2 [34,35],
quercetin 3 [36], phloroglucinol 15 or resveratrol 17 [37], two dif-
ferent strategies are used: with or without phenolic protection. On
the one hand, uncontrolled acylation leading to the introduction of
the FAs on several phenolic functions have been reported for quer-
cetin and EGCG. Penta, tetra and tri-esters of quercetin (3) were
obtained using acyl chloride of ALA [36]. Unsaturated acyl chlorides/
phenols molar ratio modulation allowed Mainini et al. to obtain
preferentially pentaesters (74%) when using phenolic/FA in a 1 to
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Fig. 1. Chemical structures of published synthetic n-3 PUFA lipophenols.
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10 ratio or a mixture of tetra and triesters (45 and 15%, respective-
ly) at 1/4 ratio. Zhong et al. [31–33] synthesized preferentially EGCG-
3′, 5′, 3″,5″-O- tetraesters of DHA and EPA 1, using acyl chloride
reagents.
On the other hand, chemical strategies, involving protection and
deprotection steps, were developed to access to (regio)selectivemono
PUFA conjugates of phloroglucinol 15, resveratrol 17 [37] or EGC 2
[34,35] (Scheme 1).
Two strategies were reported for the synthesis of 3-O-ALA-
EGC 2. Starting from hexa-acetylated EGC, the ﬁrst one [34] used
the selective deprotection of phenolic acetate in the presence of Tris
buffer to obtain 3-O-monoacetate derivative. Silylation of the phe-
nolic hydroxyls, deacetylation and ALA coupling afforded the desired
lipophenol after mild “HF deprotection”. Lin et al. [35] chose EGCG
as starting material in which the gallate group plays the role of a
protecting group of the 3-OH position, easily deprotected by LiAlH4
reduction. Despite a close reactivity of the symmetrical phenolic hy-
droxyls of the phloroglucinol (15), Crauste et al. [37] managed to
selectively remove one out of the three TIPS groups using
triethylamine-3HF, thus allowingmonoacylation by DHA in the pres-
ence of DCC/DMAP. In the samework, a chemical-enzymatic pathway
was used to couple a phenolic derivative to sn1-lyso-PC-DHA.
Scheme 1. Examples of n-3 PUFA lipophenol chemical synthesis.
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Sn1-Lyso-phosphatidylcholine-DHA was itself obtained through a
selective enzymatic hydrolysis at the sn1 position, using liposyme
immobilized from Mucor miehei, of a commercially available PC.
Desired lipophenol 16 was isolated by coupling of adipoyl-silylated
phloroglucinol, followed by HF deprotection. Finally, resveratrol-
DHA acylated either at the 4′ position 17a or at the 3 position 17b
(Crauste et al. unpublished results) were obtained using CALB as se-
lective enzyme for acylation and deprotection of the 4′ position of
resveratrol, and Et3N–HF to perform the mono deprotection of TIPS
groups on A ring of resveratrol.
At the difference with ester or amide linkages between the phe-
nolic compound and the PUFA part, non hydrolysable bounds have
been obtained [38] by synthesizing a tetrahydroisoquinoline de-
rivative 8with ALA side chain using a Bischler-Napieralski cyclization
reaction. Original anti-cancer DHA-doxorubicin conjugate (DOX-
hyd-DHA 24a) was obtained using a cleavable hydrazone linker [39].
Since pH in tumor cells is lower than in healthy tissue, the hydra-
zone bond, stable at pH 7.4, is rapidly cleaved at lower pH in
cancerous cells. DOX-hyd-DHA was synthesized by reaction of
hydrazinamide-DHA (activated by Boc-hydrazine) on doxorubicin.
3. Natural n-3 PUFA lipophenols: sources and total synthesis
3.1. Natural sources
In addition to synthetic derivatives, several lipophenols have been
isolated from natural sources. They can be related to analogues of
n-3 PUFA lipophenols, since they are linked to n-3 unsaturated
carbon chain (C11–C21) with skipped Z-double bonds separated by
bis-allylic positions and starting from the C3 of the alkyl chain. At
the difference with synthetic n-3 PUFA lipophenols, the presence
of an alkenyl part directly linked to the aromatic cycle, without ester
function, is widely represented (Fig. 2).
Usually, the crude extract rich in n-3 PUFA lipophenols is ob-
tained through extraction process (usingwater, ethanol, ethyl acetate,
methanol, diethyl ether, methylene chloride, chloroform, petro-
leum ether) from the natural sources. Puriﬁcation by
chromatographic methods (typically, silica gel column) is per-
formed to lead to isolated compounds. The percentage values given
in the following section are calculated as a fraction of the weight
of isolated lipophenol related to the weight of the extract. In some
cases percentage refers to dried or fresh matter and is mentioned
with (% from DM or FM).
Most of the natural n-3 PUFA lipophenols (Fig. 2) have been iso-
lated from vegetables or animals from marine origin. Hemiketal
spiralisone 25was isolated from Zonaria spiralis (5.3%) [40], a marine
brown algae, together with the chromone 26 (1.6%), which was also
found in several other brown algae of the Zonaria genus, like Zonaria
tournefortii [41]. Chromone 26 is presented to be a possible arti-
fact of 25, by dehydration, favored by mildly acidic conditions.
Z. tournefortii is also a source of acylphloroglucinol (ACP) deriva-
tives 37 [42] (8% and 0.3% from DM), in addition to other brown
marine algae like Zonaria diesingiana (5.3%) or Zonaria farlowii (11%
and 0.13% from fresh alga) [9]. The later also contains the speciﬁc
ACP derivative 38 (2.2%) [9]. Other algae, such as Cystophora torulosa
was shown to contain ACP 40 (0.19%) and 5-alkenylresorcinol (AR)
30 derivatives [43] (15% in mixture with other alkyl resorcinols),
Chorthippus scalaris to contain 40 and 39, while from
Chrysanthemoides monilifera and Cordyline congesta 39 was iso-
lated (<0.07% from DM) [44]. In addition to marine vegetables, some
animal marine sources have been found to produce n-3 PUFA
lipophenols. The 5-alkenylresorcinols (AR) 29, 30, 31, 35 and 36 have
been isolated from the spongeHaliclona sp (between 0.22 and 0.67%)
[45], while tyramine derivative 28 can be found in octocoralMuricea
austera from the Paciﬁc coast of Panama [46].
Apart from marine sources, natural n-3 PUFA phenols also have
been identiﬁed in different and various plant species. The macamide
27 is present in Peruvian plant Lepidium meyenii (Maca), however
its proportion in Maca extract is very low (less than 0.01% from DM)
[47]. Leaves and stems of Philodendron scadens subsp. oxycardium
contain the anacardic acid derivative 42 (0.016% of FM) and the AR
29 (0.005% from FM), which is the major allergen compound and
a weapon defense of the plant [48]. The AR 29 has various origins
and can also be isolated from liverwort Omphalantus ﬁliformis [49]
(mainly in the cuticle) and leaves of Stylogyne turbacensis [50].
Anacardic acid derivative 42 is also present in various other sources
and has been isolated from leaves of Anacardium spondias [39], and
leaves and stems of Spondias mombin [51]. The AR 32 comes from
ground aerial part of the tree Lithraea molleoides (0.16%) [52], while
AR 34 was extracted from wheat bran oil (0.007% from the oil) [53]
Fig. 2. Chemical structures of natural n-3 PUFA lipophenols.
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and traces of Z-p-O-coumaryl linolenate 41 has been observed in
the peel of cv. Annurca Apple fruits [54].
Finally, AR 33 has been isolated from amicroorganism, heterotrich
ciliate Climacostomum virens. This compound can potentially be a
defense toxin against the predatory ciliate Dileptus margaritifer [55].
Globally, the richest sources of lipophenol derivatives are from
marine origin, especially algae: 1.6 % to 11% (weight % extract) for
the genus Zonaria, and up to 15% (weight % extract) of some
alk(en)ylresorcinols for the genus Cystophora. The marine sponge
Haliclona sp. contains ﬁves different AR in amounts ranging from
0.22% to 0.58% (weight % extract). In addition, most of the natural
n-3 lipophenols derivatives are also found in plants, mainly in the
leaves and stems.
3.2. Biosynthesis and total synthesis
Zhang et al. [40] proposed a biosynthetic pathway, starting from
the monomeric phloroglucinol to access the racemic spiralisone 25
and chromone derivative 26, found in various sources of algae: after
formation of an acylphloroglucinol intermediate in the presence of
acetyl-CoA, elongation via a Claisen condensation on an activated
fatty acid would lead to the incorporation of the polyunsaturated
part. The resulting acylphloroglucinol β-diketone would undergo
intramolecular cyclization to afford the spiralisone derivative, then
the chromone upon dehydration. While following the same reﬂec-
tion, El Hattab et al. [56], supposed that Claisen condensation could
be performed on a pentaketide precursor to form directly the
acylphloroglucinol β-diketone.
From the chemical point of view, the ﬁrst total synthesis of 26
was reported by Anwar et al. [57] (Scheme 2), in six steps starting
from an ester of EPA, in a 14% overall yield. The ethyl ester of EPA
is ﬁrst transformed into a terminal alkyne through its hemireduction
to the aldehyde, followed by a Colvin rearrangement. This alkyne
is then coupledwith 2,4,6-tris(methoxymethoxy)benzaldehyde using
n-BuLi. After oxidation of the obtained secondary alcohol, and
deprotection of the phloroglucinol moiety, intramolecular Michael
addition under basic conditions, afforded the desired chromone 26.
AR and ACP represent the largest family of natural lipophenols.
In plant, their biosynthesis is believed to follow the polyketide
pathway (Scheme 3): in a few words, a fatty acylCoA starter un-
dergoes three condensation reactions with malonylCoA leading to
a tetraketide intermediate [56,58], which can undergo two ring for-
mation mechanisms: an aldol condensation (followed by an easy
loss of carboxyl) would conduct to AR structures, while Claisen con-
densation allows to the formation of ACP. However, hypothesis of
polyunsaturated long-chain AR biosynthesis has also been pro-
posed for AR compound 33, in which the polyunsaturated part would
be formed after cyclization and decarboxylation of a C18-polyketide
[55,59] (Scheme 3).
4. n-3 PUFA lipophenol activities
4.1. Antioxidant and anticarbonyl stress activity
Most of the combinations of n-3 PUFA with natural antioxi-
dants such as ﬂavonoids, have been proposed to increase their
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lipophilicity for two main purposes: (1) to increase their preser-
vative effects against oxidation [10,14] of lipophilic food matrices;
(2) to circumvent their use limitation, due to their low skin/cell per-
meability, solubility or bioavailability in the dermocosmetic,
nutraceutic or therapeutic applications, beneﬁtting additional health
promoting effects related to the n-3 PUFA moiety.
To date, many in-vitro tests (test-tube or in cell assays) are avail-
able to detect, quantify and compare antioxidant capacity and ability
of chemicals to protect a substrate against oxidation, but unfortu-
nately none of them are universal. When comparing antioxidant
results, it should always be kept in mind that the result of those
tests will depend not only on the direct activity of phenolic com-
pounds, but also on other parameters, such as their own solubility,
as well as the one of the substrate (to be protected from oxida-
tion) and on the lipidic and/or aqueous medium in which the assays
are performed. Using two different methods, discrepancies between
the found activities are unavoidable. Different experimental con-
ditions in terms of solubility, of accessibility of the oxidant to the
oxidation site, of the location and/or of the distribution of the an-
tioxidant, will make the antioxidant potencies diﬃcult to compare
[60,61]. Eﬃcacy of antioxidant linked to PUFA compared to the initial
phenol is mainly reported using homogeneous DPPH radical-
scavenging activity assay, sometimes ABTS, FRAP or ORAC assays.
In the case of protection of lipophilic food matrix, β-carotene lin-
oleate method, rancimat test, or thiobarbituric assay (compared to
α-tocopherol or butylated hydroxytoluene (BHT) activity) have been
employed. It was surprising to observe, that, to the best of our knowl-
edge, most of the evaluation of antioxidant activity of n-3 PUFA
phenol were performed in cell free assay. Unfortunately, such assays
do not take into account the enzymatic cleavage of the ester bounds,
which, in some lipophenolic structures, could free the lipid part and
unmask the active phenolic functions.
All n-3 PUFA-phenol esters tested in literature showed radical
scavenging activity in the DPPH radical assay [10,12,14,17,33,36]. It
is worthy of note that even though the structures contain an easily
oxidizable PUFA, the lipidic part appears to be protected from ox-
idation by conjugation with phenolic residue. To date there is not
a clear correlation between the introduction of the lipid part and
the increase or the decrease in the radical scavenging capacity of
the phenolic derivative. There is an important relationship between
the hydrophobic nature of the new lipophenol and its activity, which
will depend on the nature of both the lipid and the phenolic part
and also on the binding position.
According to Zhong et al. [33] EPA and DHA tetra esters of EGCG
(3′, 5′, 3″, 5″ O esters, 1) exhibited both a greater antioxidant ac-
tivity in scavenging DPPH° (determined by electron paramagnetic
resonance-EPR) than EGCG itself. In this study, Zhong et al. suggest
that the lipophenol with enhanced lipophilicity may have greater
accessibility to the lipophilic DPPH radical than the hydrophilic ﬂa-
vonoid. In addition, it is proposed by the authors that acylation on
3′, 5′, 3″ and 5″ positions, may reduce electron density of the O–H
bound at position 4′ and 4″ (due to the electron withdrawing prop-
erty of both acyl groups in ortho position), thus enhancing the ability
to scavenge radical in these position. On the contrary, quercetin
(penta, tetra, and tri) ALA esters 3 display a lower antioxidant ac-
tivity with respect to free quercetin in both DPPH (IC50: 4.72 vs
triesters: 107.26 μg ml−1) and ABTS assay (TEAC: 1930 vs triesters
1.33 mg g−1) [36]. Triesters, in which the OH at positions 5 and 3
are free, display a higher activity than pentaesters having only 5-OH
free. This result highlighted the relevance of a free OH at the 3 po-
sition for the design of lipophenolic quercetin antioxidant, compared
to free OH at the 5 position able to create intramolecular H-bonding
with the carbonyl function. It is worthy of note that the antioxi-
dant activity of PUFA-quercetin increases with the number of
unsaturations in the FA. Similarly, when exposed to DPPH°, free DHCA
manifested higher radical scavenging ability (62%), than its lipid (ALA-
acyl glycerol) conjugate (compound 14, only 19%) [17]. According
to Sabally team, this huge drop in its radical scavenging ability could
be attributed to limitation in conformational changes in the
lipophenol derivative. Mbatia et al. [10] reported the same obser-
vation with ALA, EPA and DHA vanillyl esters 10, whose the radical
scavenging activities were lower than for vanillyl alcohol itself. A
great increase in hydrophobicity may have resulted in decreased
vanillyl esters solubility in the tests medium. Again, with the rutin
5, phloridzin 6 and isoquercitrin 7 PUFA-derivatives, and even though
the omega-3 acids were linked to the sugar moieties (which is not
considered to be the crucial part for a molecule to display such a
property), only the PUFA-rutin esters 5 had the same [10] or just a
weaker [14] capacity to scavenge radicals than the free rutin, in the
DPPH assay. Despite a substantial antioxidant activity in FRAP and
DPPH assays, phloridzin 6 and isoquercitrin 7 esters (ALA, EPA, DHA)
have a lower free radical scavenging activity than the parent com-
pounds. This effect may be attributed to the steric hindrance of PUFA
since the number of double bonds of the FA seems to inﬂuence the
antioxidant capacity. However, the correlation is not working in the
same way, depending on the antioxidant assay performed.
When protection of acyl glycerol enriched in PUFA from oxida-
tion (TBARS assay) is tested in a lipophilic medium, rutin and vanillyl-
PUFA esters 5 and 10 showed lower antioxidant activity than BHT
but were stronger than the lipophilic α-tocopherol, in oil emul-
sion [10]. However, none of them was better antioxidant than any
of these two references in ﬁsh oil system. In contrast, rutin-ALA ester
5 exhibited the best inhibition of lipid peroxidation in β-carotene
linoleate system comparable to that of BHT [14]. Inhibition was
higher than rutin and as active as rutin-palmitate and stearate. Those
results reported by Viskupicova et al. also clearly demonstrate that
hydrophobicity has an impact on the antioxidant capacity of rutin
derivatives in lipophilic food systems (sun ﬂower oil), since better
protections were observed using long-chain FA (C16–C18) com-
pared to shorter ones (C4–C10). In this case, the numbers of double
bond in C18 FA did not inﬂuence the activity. Natural Z-p-coumaryl
linolenate 41 showed the same ability (50%) to inhibit the produc-
tion of peroxides in the methyl linoleate autoxidation assay as its
linoleic analogue [54].
Oxidative and carbonyl stress are closely related since most of
toxic carbonyl stressors may come from lipid peroxidation end prod-
ucts. Recently, Crauste et al. [37] developed lipophenol derivatives
in order to reduce oxidative and carbonyl stress in retina patholo-
gies. PUFA such as DHA was selected because of its high proportion
in retina cell membranes, suggesting a possible vectorization to target
retina tissues. Isopropyl-phloroglucinol-DHA conjugate 15 was able
to protect ARPE-19 and primary cells of the retinal pigment epi-
thelium (RPE) against both H2O2 and trans-retinal stress (Crauste
et al. to be published and [37]). In ARPE-19 cells assay, DHA
lipophenolic conjugate allowed to increase cell survival up to 40%
in presence of a toxic concentration of trans-retinal, while free DHA
and isopropyl-phloroglucinolmixturewas inactive. Protection against
trans-retinal toxicity could be attributed to the trapping of the toxic
aldehyde (carbonyl scavenger) leading to a chromene derivative.
Among several PUFA conjugates ALA and DHA phloroglucinol 15 pre-
sented higher in vitro protection against carbonyl stress, and
saturated C22 fatty acid conjugation led to a weak activity (Crauste
et al. unpublished result).
Interestingly, natural EPA chromone analogue 26 showed cel-
lular protective effects of HepG2 cells against cellular lipid
peroxidation (CLPAA assays), and reactive oxygen species (CAA
assays) [62]. The activity of more lipophilic chromone 26was similar
to quercetin in the CLPAA assay (respectively IC50: 14 and 10 μM)
but was less active in the CAA assay (respectively IC50: 160 and
71 μM).
Most of the results reported in literature with the DPPH assay,
are consistent with a decrease of radical scavenging capacity after
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introduction of a lipidic moiety on phenolic structure. However, dif-
ferent experiment performed inmicrosomial suspension, in emulsion
system or in cellular media, may probably lead to different conclu-
sions, regarding the capacity of lipophenol to maintain antioxidant
activity and better protection in lipophilic biological or food system
media. Additional in vitro and cellular assays must be necessary to
fully address the question of lipophenol antioxidant activity.
4.2. Anti-cancer activity
Why using n-3 PUFAs to enhance anti-cancer activity of phe-
nolic compounds? The answer could be explained by several rational
points. First of all epidemiological studies pointed out that diet rich
in n-3 PUFAs may lower proportion of cancer incidents. Indeed, n-3
PUFAs and PUFA metabolites are involved in various cellular pro-
cesses thatmay help to lower tumor progression or to protect healthy
tissues during chemotherapy: inﬂammation, cellular adhesion,
energy metabolism, apoptosis signaling pathway . . . As an example,
PUFA metabolites such as eicosanoids, resolvins or protectins are
reported as potent anti-inﬂammatory derivatives that may affect
tumor growth due to the close relation between inﬂammation and
cancer. According to PUFA activities in this domain, it appears in-
teresting to conjugate PUFAs to obtain a synergism with cytotoxic
drugs. Moreover, it has been demonstrated that PUFA uptake is con-
siderably elevated in tumor tissues, thanks to tumor-speciﬁc
transport of HSA-bound complex. Here, PUFAs are used as bio-
chemical precursors and energy sources for the cell. Based on this
observation, PUFA conjugates are perfect candidates to not only in-
vestigate improvement in pharmacokinetics and distribution of
poorly bioavailable drugs, but also acquire at the same time a spe-
ciﬁc accumulation of the cytotoxic drug in tumor cells and tissues.
Among lipophilic anti-cancer derivatives, the most studied was
the one linked on doxorubicin drug (DOX), responsible for DNA in-
tercalation and inhibition of topoisomerase II, which has been used
for the treatment of various types of cancer. DOX-ALA and DOX-
DHA 24 have been developed to reduce systemic toxicity and
enhance therapeutic index. In vitro activities of DOX-hyd-DHA (linked
through a cleavable hydrazone bound, 24a) were lower than DOX
against L1210 leukemia cell lines. Whereas, in vivo activities in mice
models (mice injectedwith L1210 leukemia and B16melanoma cells,
IP administration, optimal dose 16 mg/kg and 30 mg/kg respec-
tively) improved the lifespan, lowered the weight loss and doubled
the tumor growth inhibition [63]. In the study reported by
Effenberger et al. [64], DOX-hyd-ALA 24a showed an advantage in
avoidingmultidrug resistance induction. The cytotoxicmode of action
was largely apoptotic in 518A2, HL-60, KB-V.1 and MCF-7 cancer
cell lines. Involvement of caspase-3, -8 and -9, were different de-
pending on the tested cell lines. In addition, signiﬁcant increase in
ROS has been observed. However, saturated heptadecanoyl ana-
logue reduced metabolic activity of the cell lines more than the
unsaturated DOX-hyd-ALA. In parallel, Liang et al. [65] studied in vitro
(MCF-7, MDA-MB-231, and HepG2) and in vivo (mice) activities of
DOX-ALA and DOX-PA (palmitate) either linked through an hydra-
zone bound (DOX-Hyd-ALA 24a) or by the daunosamine residue
(DOX-ami-ALA 24b). In this study, saturated or unsaturated fatty
acid on the 3′ amino group lead to a decrease in antitumor activ-
ity compared to DOX and DOX-hyd-ALA. DOX-hyd-ALA showed the
highest cytotoxicity, stability in bloodstream, and fastest release of
DOX in acidic tumor cells. As observed by Huan et al. [25] for DOX-
ami-ALA, increase in cytotoxicity of DOX-Hyd-ALA was correlated
to rapid internalization/uptake of the PUFA conjugate compared to
free DOX. Regarding DOX release, cellular uptake and cytotoxicity,
DOX-Hyd-ALA presented an advantageous biological proﬁle com-
pared to DOX, DOX-PA or DOX-ami-ALA. To end, in vivo evaluation
of DOX-hyd-ALA in tumor-bearing nude mice (IV administration
7.5 mg/kg, compound in solution in normal saline containing 5% v/v
PEG400), enhanced therapeutic eﬃcacy of DOX with less systemic
toxicity and greatly increased the content of DOX in tumor tissue
with a signiﬁcant decrease of its proportions in other organs.
Another inhibitor of DNA topoisomerase II, the 4′ demethyl
deoxypodophyllotoxin (DDPT 23), showed strong in vitro toxicity,
but without in vivo activity. FA-DDPT have been synthesized with
the hope that esteriﬁcation with FAs would reduce the metabolic
excretion and enhance its in vivo eﬃciency [27]. Despite a lower
cytotoxicity in in vitro assays (A-549 and SK-MEL-2 cell lines), long
chain FA (C16–C22) presented better in vivo antitumor activity
(60 mg/kg) than short alkanoyl acid derivatives (C2–C6), probably
due to an increased resistance to esterase, that delay the metabol-
ic excretion of phenolic hydroxyl group. The number of double bonds
seems to play a role in the in vivo and in vitro activities, with a dif-
ferent (positive or negative) correlation depending on the length
of the FA.
Other examples can be described, such as Dohevanyl (DHA vanillyl
amide 11), a PUFA analogue of capsaicin, that induced caspase-
dependent apoptosis MCF-7 cells (via a caspase-3 independent
pathway), with better eﬃciency than capsaicin [26]. The conjuga-
tion of juglone (5-hydroxy-1,4-naphthoquinone) with unsaturated
FA (21) was able to considerably enhance inhibition of DNA poly-
merase replicative α and mitochondrial γ, compared to the initial
phenol [20]. The inhibition effect of acyl conjugates ranked as follow
C18:1 > C20:5 > C22:5 > C18:2 > C18:3, with saturated derivative
C18:0 acyl juglone as active as the individual compound. The same
inﬂuence of the FA part was observed for the growth inhibition of
human colon carcinoma cultured cell (HCT116), suggesting that
cancer cell growth prevention by those derivatives may be attrib-
uted to DNA polymerase inhibition. However, it is worthy of note
that conjugation of cytotoxic derivatives with PUFA does not nec-
essary lead to an increase of the activity. Ahn et al. [23] synthesized
acyl shikonin analogues, including shikonin-ALA 22, which showed
negligible DNA-topoisomerase I inhibition in a cell free enzymatic
assay.
Signiﬁcant ameliorations of in vitro and in vivo activities were
also reportedwith ﬂavonoid polyphenols. Rutin-ALA 5, allowed over-
coming solubility problems compared to native compounds, andwas
able to decrease the production of VEGF, a regulator of tumor induced
neoangiogenesis, in K562 lymphoblastoid cell lines [11]. In this assay,
C18 fatty acid esters of rutin having one, two or three double bonds
presented the same activities, and rutin was not active at all.
A mixture of EGCG and tetra/penta esters of DHA (1), was evalu-
ated in azoxymethane-induced colonic carcinogenesis mice [31] (oral
diet, supplementation in EGCG-PUFA 0.5%). The mixture was able
to reduce the total number of colon large colonic aberrant crypt foci
(ACF), a predictive biomarker of colorectal cancer. Increased activ-
ity compared to EGCG was attributed to an improve lipophilicity,
thatmay alters in vivometabolism. Pro-inﬂammatorymediators such
as nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), known
to be involved in carcinogenesis promotion, were down-regulated
by the mixture in a dose-dependent manner. Hypothesis of a syn-
ergism between the polyphenol and the FAs part is expressed by
the author.
5α-reductases are microsomal enzymes, that catalyze the re-
duction of double bond of a variety of steroid derivatives, and which
may be involved in development and progression of prostate cancer.
Since EGCG and ALA have been identiﬁed separately to inhibit such
enzyme, Hiipakka et al. [34] and Lin et al. [35] studied the activity
of EGC-ALA conjugates 2, replacing the gallate moiety by ALA or by
its saturated analogue. Probably due to a combined functionality
of both phenolic and PUFA parts, the EGC-ALA conjugate showed
potent 5α-reductase type 1/2 inhibition (IC50 = 7 μM for type 1) com-
pared to EGCG, EGC (IC50 > 100 μM) or saturated stearate lipophenol
(IC50 = 42 μM) in whole cell-assay. Results were different in cell free
assay depending on the study performed. Unlike Lin et al. [35] who
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reported increased activity of EGC-ALA or EGC-stearate (IC50 = 0.73–
0.78 μM) compared to EGCG (IC50 = 6.29 μM), Hiipakka et al. [34]
presented a close signiﬁcant activity for EGCG and EGC-ALA, and
a weak inhibition using EGC-stearate.
Interesting results were reported by Siddiqui team [24,66], which
tried for once, to enhance anticancer properties of n-3 PUFAs in
breast cancer, by making phenolic ester. DHA and EPA esters of
propofol 19, demonstrated greater potency for inhibiting cell growth
(MDA-MB-231), slowingmigration, increasing cellular adhesion, and
initiating apoptosis compared to the combination of propofol with
DHA or EPA. By comparing stability and activity of ester and amide
analogues of propofol-DHA, it was demonstrated that ﬁrst, this ester
linkage should not be cleaved in biological media, and second, that
the activity depends on this stability. Moreover, unlike free DHA ac-
tivity, there was no observed effect on PPARα or PPARγ, suggesting
that DHA-propofol action followed an independent mode of action
(probably inhibition of histone deacetylase – HDAC).
Among the natural products, cytotoxicity of the ALA-
alkylresorcinol analogue 29 was observed on human breast cancer
(MCF-7) and human lung cancer (NCI–H460) cell lines [50]. The n-6
LA analogue was equipotent compared to 29. After comparison with
per-acetylated analogues it was concluded that free phenolic hy-
droxyl groups are required for the anticancer activity. Another natural
lipophenolic AR (34), showed a growth inhibition on human colon
cancer cell lines, HCT-116 and HT-29 (MTT assay) [53]. Saturated
or longer carbon chain analogues were tested and the results seemed
to indicate that increasing the length of the side chain diminished
the inhibitory activity (range from C17 to C25) and the existence
of one double bond at least improved the activity. However, ac-
cording to the authors the anticancer effects of ARswere very limited.
4.3. Interaction with endocannabinoid system
Research of cannabimimetic that could modulate endogenous
cannabinoid system (ECS), have prompted researchers to develop
FA amide based on the anandamide structure. Bezuglov et al. [18]
reported activity of dopamine-EPA and dopamine-DHA conju-
gates 12, showing signiﬁcant in vivo activity (IP administration 10mg/
kg, compound in solution in physiologic saline/tween20 mixture)
in the tetrad test (production of catalepsy, hypothermia, analgesia
and inhibition of locomotion), used for evaluation of cannabimimetic
properties of drugs. The results suggested that they belong to the
family of CB1-cannabinoid receptor agonist, and highlight the im-
portance of at least 4 double bonds in the chemical structure of
cannabimimetic. In addition, Bisogno et al. [19] studied the bio-
chemical properties of unusual n-3 PUFA-dopamine (stearidonoyl
C18:4, eicosapentaenoyl C20:5, docosapentaenoyl C22:5) and ALA-
dopamine, and reported their inhibition of protein of endogenous
endocannabinoid system such as fatty acid amide hydrolase (FAAH),
and anandamide transporter, as well as the binding to cannabi-
noid receptor CB1. The presence of the catechol structure of
dopamine is believed to stabilize the enzyme substrate complex in
the active site of FAAH and enhance aﬃnity with CB1.
Looking for the development of novel analgesic derivatives, Melck
et al. [67] designed PUFA derivatives based on capsaicin and
anandamide structures, able to interact with endocannabinoid re-
ceptors, while preserving their capability to activate vanilloid
receptors (TRVP1). Among them, N-acyl-vanillyl-amide-ALA 11, in-
hibited anandamide accumulation (RBL-2H3 cells), was a weak
inhibitor of FAAH, presented selectivity for CB1 vs. CB2 receptor and
was able to interact with TRVP1. However, omega-6 analogue (C20:4,
arvanil) was a better candidate to develop “hybrid” cannabinoid/
vanilloid agonist derivative. Following the same goal, N-acyl-
tetrahydroisoquinoline-DHA 9 was tested on TRPV1 receptor
expressed in HEK293 cells and exhibited partial agonist effect [30].
Regarding natural lipophenols, maca extract, which presents weak
concentration of macamide 27 (an analogue of N-acyl-vanillyl-
amide-ALA 11), exhibits in vitro and in vivo (IV administration in a
mixture water/poly-vinyl-pirrolidone, 3 mg/kg) neuroprotective ac-
tivity, as reported by Pino-Figuera et al [68]. In addition, thanks to
structural similarity to endocannabinoid, isolated macamide 27, has
been found to interfere with different proteins of the ECS [69,70]:
inhibition of FAAH enzyme and moderate binding aﬃnity for CB1
receptor. It was reported that those activities are signiﬁcantly im-
proved if the lipophilic chain is replace by the LA analogue.
Contradictory results describing the importance of the methoxy
group was presented depending of the research team and the test
performed.
4.4. Anti-inﬂammatory activity
Various studies support beneﬁcial effects of polyphenols in
chronic inﬂammatory diseases that may be explained, in part, by
inhibition of transcription factor NF-kB activation, involved in gene
expression of pro-inﬂammatory mediators such as INOS and COX-
2. Since n-3 PUFAs and their metabolites are reported to exhibit an
inhibitory effect on inﬂammation, Zhong et al. [32] evaluated the
potency of a mixture of EGCG-DPA (docosapentaenoyl, C22:5 n-3)
tetra and penta esters 1 to inhibit the production of pro-
inﬂammatory mediators, nitric oxide (NO) and prostaglandin E2
(PGE2), in lipopolysaccharides (LPS)-stimulated murine RAW 264.7
macrophages. At a concentration ranges around 50 μg/ml, EGCG-
DPA esters inhibited NO and PGE2 production in a greater extent
than did the free FA. As observed for, pure EGCG-DHA, EPA and
Stearic tetra esters, EGCG-DPA exhibited down regulation effect of
iNOS and COX-2 biosynthesis, while DPA alone exerted insigniﬁ-
cant effect on their transcription. Contribution of DPA to anti-
inﬂammatory activity may pass through a different mechanism.
Enhance cellular absorption and additional contribution of the fatty
acid side chain, are proposed to comment increase eﬃciency of
lipophenols.
Greater inhibitory effect of the inﬂammatory cytokine TNF-α pro-
duction, was also found using Juglone-PUFA 21 (DHA, EPA and ALA)
compared to the juglone, in cultured mouse macrophage RAW264.7
[20]. Close activity was also observed for saturated analogues having
C18 and C12 chain length, while C6, C2 and C3 derivatives were
poorly active. Comparable activities were reported for those esters
in a mouse ear inﬂammatory test, to reduce inﬂammation caused
by 12-O-tetradecanoylphorbol-13-acetate (TPA).
Inspired by the discovery of C22 enone FA (EFOX, electrophilic
oxo derivatives), DHA and DPA metabolites generated during in-
ﬂammation process by COX-2, Dang et al. [29], compared the anti-
inﬂammatory activity of a wide range of N-acyl FAs (saturated FA
and PUFA) including N-acyl-dopamine 12, N-acyl vanillylamine 11,
and their enone fatty acid analogues. N-acyl dopamine conjugates
exhibited the most potent inhibitory activity on the production of
NO, cytokines IL-1β, IL-6 and TNF-α, in LPS-activated RAW264.7. The
activity was strongly dependent on the nature of the fatty acid part,
in the order, enone FAs, PUFAs, monosaturated and saturated FAs,
suggesting the interest of PUFA metabolites in the activity of
PUFA-phenols.
4.5. Enzymatic inhibitor
Some n-3 lipophenols have been investigated as enzyme inhibi-
tors [12,13,21,22], using the lipid chain as hydrophobic part which
would modulate the aﬃnity for the enzyme. Interesting compari-
son of the tyrosinase enzyme inhibition of phloridzin and
isoquercitrin esters (6 and 7) was performed using stearic, oleic (OA),
linoleic (LA), ALA, EPA and DHA fatty acids [12]. The precursor phlo-
ridzin exhibited weaker tyrosinase inhibition as compared to
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isoquercitrin (at 1 mM, 16% and 54% respectively). In both cases,
introduction of speciﬁc n-3 FAs in the polyphenol structure lead to
a strong increase in inhibition potential. However, depending on the
polyphenols studied, introduction of DHA or ALA did not inﬂu-
ence the activity in the same way: phloridzin activity was especially
enhanced using DHA (91% of inhibition), while isoquercitrin needs
ALA linkage to reach around 86% of inhibition on the same target.
Surprisingly, inversion of PUFA i.e. used ALA on phloridzin and DHA
on isoquercitrin, drops inhibitory activity below precursor’s one. De-
pending on the polyphenol structure and their ﬂexibility, the
molecule must be able to adjust differently the position of the FA
and the phenolic function to obtain better interaction with the active
site of the enzyme. Moreover, number of double bonds in the lipidic
chain will necessary change the ﬂexibility of the lipophenol con-
jugate and thus inﬂuence its conformation. Those results highlight
that for a same target, different kinds of PUFA may be beneﬁcial to
increase the aﬃnity of polyphenolic drugs for the active site.
Among, serine protease enzymes, namely Trypsin, Thrombine,
Urokinase and Elastase, the acylation of rutin with medium to long
FA (C16–C22, including ALA 5), provide signiﬁcant improvement in-
hibitory activity only on Thrombine protease [13]. Viskupicova et
al., suggested that the enhanced hydrophobicity, would provide in-
teraction with hydrophobic region of the enzyme. The hypothesis
was supported by QSAR analysis, showing correlation (correlation
coeﬃcient 0.7) between inhibitory activity and molecular volume,
polar surface area and number of hydrogen bond acceptors. The chain
length (C16–C18) appears to be a deciding factor for the activity
while the number of double bound was less signiﬁcant.
Those reported enzymatic cell free assays, point it out that
lipophenol derivatives might exert their activity not only by in-
creasing cell membrane penetration or fostering a synergistic effect
between the phenolic and the n-3 PUFA, but that the entire
lipophenol structures might be indispensable and responsible for
increasing bioactivity. In future, molecular modeling would have to
conﬁrm this fact. Moreover, extra or intracellular proteins that are
reported to bind phenolic or PUFA derivatives (such as albumin,
PPAR . . .), should be considered has potential target to study the ac-
tivity of this new kind of lipophenol derivative.
This reﬂection could also be supported by natural lipophenol ac-
tivities, bearing a non-hydrolysable n-3 PUFA part. In vitro cell free
assays of hemiketal spiralisone 25 and chromone 26 (both EPA ana-
logues) highlighted inhibitory activities (with IC50 < 10 μM) against
kinase targets, casein kinase 1δ (CK1δ), cyclin-dependent kinase 5
(CDK5/p25) and glycogen synthase kinase 3β (GSK3β), which are
involved in Alzheimer’s disease [40]. Interestingly the crude alga
Z. spiralis extract presented kinase inhibitory potency, most prob-
ably linked to the cumulative effect of multiple moderately potent
spiralisone inhibitors. This effect was especially showed for the in-
hibition of β-secretase BACE which is also involved in Alzheimer’s
disease. In addition, another example is given by the reported ac-
tivity of the natural alkenylphenol ALA-anacardic acid derivative 42
[71]. In order to reduce bacteria resistance to antibiotics, 42 was
tested for its inhibitory activity on bacterial β-lactamases, enzymes
responsible for the inactivation of β-lactam antibiotics. It proved
its eﬃciency against β-lactamase enzyme of Escherichia coli JT4 (TEM-
1) (IC50 = 5 μM), and had a lower but signiﬁcant level of inhibition
against β-lactamases of E. coli K12 (PSE4) (IC50 = 10.1 μM),
Enterobacter cloacae P99 (IC50 = 16.5 μM) and Pseudomonas aeruginose
A (IC50 = 40.5 μM). For the two last one, 42 displayed a better ac-
tivity than the β-lactam drug clavulanic acid.
4.6. Antibacterial and antiparasitic activities
Several natural lipophenolic compounds showed antibacterial
activities. In addition to inhibition of kinase, hemiketal spiralisone
25 and chromone 26 exhibited moderate growth inhibitory activ-
ity (IC50 = 2.5–10 μM) against gram positive bacteria Bacillus subtilis
(ATCC 6051 and 6633) [40]. The antibacterial properties of the crude
Z. spiralis extract was more expended than isolated lipophenols. This
could be explained by the cumulative concentration effect of mul-
tiple mildly bioactive spiralisones.
EPA-acylphloroglucinol derivatives 37 and 38 displayed anti-
bacterial activity (measures of microbial growth inhibition), tested
in vitro on Staphylococcus aureus and Bacillys subtilus [9]. The com-
pound 38 bearing a methoxy group is more active than 37 for the
inhibition of S. aureus, while 37 is more potent than 38 against B.
subtilus. Moreover, anacardic acid derivative 42 showed pro-
nounced antibacterial effects on Bacillus cereus, Streptococcus pyogenes
and Mycobacterium fortuitum [51], as its LA analogue. According to
mono-saturated and longer carbon chain derivative evaluations, it
was reported that the antibacterial activity drops with the decreas-
ing number of unsaturation and with the increasing number of
carbon on the lipid chain. The natural compound 42 also dis-
played weak antibacterial activity against Gram-positive organism
(Staphylococci spp) [71].
ALA-Anacardic acid derivative 42 is not only an antibacterial agent
but presents also antiparasitic (molluscicidal) activity against the
snail Biomphalaria glabrata (LC50 = ± 1 ppm), an intermediate host
in the schistosome life cycle [51]. The tyramine derivative 28 dis-
played moderate antiprotozoal activity (IC50 = 38 μM) against
Plasmodium falciparum as reported by Gutierrez et al. [46]. Com-
plementary assays with synthesized analogues suggested that longer
FA lead to increased antiplasmodial activity, while the presence of
polar groups on the FA chain decreased the activity. The ALA-AR an-
alogue 29 could also be considered as antiparasitic agent, as its LA
analogue [50]. In vitro tests of 29 exhibited moderate activity
(IC50 = 25 μM) against intracellular form of the parasite Trypano-
soma cruzi (Chagas disease), and a signiﬁcant activity (IC50 = 0.6 μM)
against a unicellular kinotoplastid prozoane parasite Leishmania
donovani (human visceral leishmaniasis). As observed for cytotox-
icity activity (part 4.2.), free phenolic hydroxyl groups are required
for the antiparasitic activity. It was also demonstrated the impor-
tance of the bis-allylic positions. Moreover, this compound showed
a stronger antiparasitic activity compared to catechol, suggesting
the importance of the lipid part in the activity. Another AR 32 dis-
played paralyzing effects on the nematodes Trichostrongylus
colubriformis (infective larvae for sheep) [52]. It was less potent com-
pared to LA analogue, and more active than the analogue trans n-3
(Z,Z,E). Unfortunately, in vivo evaluation (50 mg/kg) showed a lack
of activity probably due to enzymatic degradation, weak
bioavailability and difference in life stage of the parasite.
While the mechanism of action of those natural lipophenols has
not been entirely studied, the literature highlights their interest-
ing biological properties as antibacterial and/or antiparasitic
derivatives, suggesting that theymay serve a defensive role in plants
[58] and in human. Additionally, regarding antibacterial and anti-
parasitic activities of LA and saturated analogues of some of the
reported lipophenols, the PUFA part on those compounds was not
absolutely necessary to exert an activity.
5. From administration to the cells
As reported all along the review, biological activity of n-3
lipophenol has been mainly evaluated by in vitro (cellular or cel-
lular free) assay, a few studies reported in vivo evaluations on mice
or rats, but currently no clinical test on human is reported for such
derivatives. For cellular assays, due to the weak solubility of
lipophenols in aqueous media, the tests are performed using the
solubility of compound in DMSO or Ethanol (with a ﬁnal concen-
tration below 0.1%), that allows the lipophenol derivative to be
solubilized in the cell culture medium and to access cell. To illus-
trate this fact, Huang et al. reported that despite weaker aqueous
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solubility, doxorubicine conjugated with ALA was taken up more
rapidly and in greater amount by cancerous cell lines compared to
free doxorubicine [25]. For in vivo administration, since DMSO an
ethanol are not acceptable vehicle, the lipophenol could be dis-
solved in physiologic saline solution in the presence of PEG [35] or
using small proportion of detergent such as Tween20 [18], to afford
lipophenol solution able to be injected by IV or IP processes. For-
mation of complex with albumin, as performed in the case of PUFA
administration [72], may also be an alternative for in vivo admin-
istration, since both PUFA [5,6] and polyphenol [73] are known to
bindwith several sites of albumin, without necessarily affecting their
activity [74].
Once administrated, what would be the stability of those types
of derivatives? Most of the n-3 lipophenol have been synthesized
by forming an ester bound between the phenolic and the PUFA parts.
After oral administration, lipophenol linked through ester linkage
may probably be cleaved during the digestive process. One can
imagine that they will be highly metabolized, or rapidly elimi-
nated as are most of the polyphenols after oral ingestion. However
Zhong et al. reported an increased activity of the EGCG-PUFA esters
(1) compared to EGCG after oral administration [31]. Liang et al.
studied the stability of DOX-hyd ALA 24a and DOX-ami-ALA 24b in
rat serum [65]. The results clearly demonstrate the stability of the
hydrazone and the amide bound that released less than 25% of
Doxorubicine in 48 h. Siddiqui et al. studied the stability of Propofol-
DHA (19), a diisopropylphenol conjugate of DHA, in human and
mouse serum at 37 °C for 2 h [66]. Probably because of steric hin-
drance of the isopropyl groups, the ester linkage was not cleaved
at all. However this could be different with other lipophenols, de-
pending on the chemical structure of the compounds. In future it
would be important to study their stability inside of the cell, in pres-
ence of cellular esterases.
In the systemic circulation, after IV or IP administration, the
biodistribution of the lipophenol will necessarily depend on their
ability to bind plasma protein. The degree of binding to the major
plasma protein, albumin, may have consequences on the rate of clear-
ance of metabolites and for their delivery to cells and tissues. One
of the mechanism of free PUFA transport is based on their binding
with HSA, allowing them to reach lipophilic membrane despite their
poor solubility in water [3,75]. This major plasma protein is also able
to extensively bind polyphenol depending on their chemical struc-
ture [73]. Acylation of polyphenol may probably decrease the aﬃnity
of the phenolic part for albumin but the PUFA part should be able
to compensate this loss of aﬃnity. Lipophenol binding to human
plasma albumin has been reported for DOX-hyd-ALA 24awhich pres-
ents a protein binding rate of 98.7%. After IV administration (7.5 mg/
kg) this compound was able to reach heart, liver, lung and kidney
and speciﬁcally the tumor tissue (12 μg/g of tissue). This result could
be compared to the one of other PUFA conjugate, such as DHA-
Paclitaxel, which showed an extensive bonding with HSA (99.6%)
and was relatively stable in blood circulation despite ester linkage
between the two parts of the conjugate. Stability andmetabolization
of each lipophenol derivative will necessarily depend on their chem-
ical structure and remains to be investigated individually for each
of them in order to adapt, linker, formulation, doses, way of ad-
ministration, and reach optimum systemic concentration and cellular
uptake.
6. Conclusions and future directions
Chemical structures of natural and synthetic n-3 PUFA phenol
derivatives have been reviewed. The design of the entitled com-
pounds is most of the time aiming at enhancing biological eﬃciency
by increasing lipophilicity of naturally “water soluble” polypheno-
lic molecules. From the synthetic point of view, access to n-3
lipophenols is easily performed using classical coupling reagents
used in organic chemistry. Eﬃcient utilization of enzymatic system
such as CALB lipase was used to perform controlled introduction
of PUFAmoiety on sugar residues of ﬂavonoids. Chemical protection/
deprotection strategies have also been successful to access mono
PUFA-polyphenolic conjugates. Regioselective functionalization of
the phenolic part by the fatty acid(s) is a tedious task yet, even
though enzymatic reactions are helpful for some positions. In future,
screening and modiﬁcation of enzymatic lipase would offer addi-
tional possibility for lipophenol synthesis. Moreover new pathways
have to be explored in the ﬁeld to successfully complete the full range
of lipophenol derivatives using practical syntheses.
Regarding n-3 lipophenol evaluations, those derivatives have
showed a wide range of interesting biological activities: antioxi-
dant, anti-inﬂammatory, anti-cancer, anti-bacterial, anti-parasitic
activities . . . Depending on the target and on the lipophenol struc-
tures, the role of the n-3 PUFA part was signiﬁcantly different and
the beneﬁcial effect of the introduction of the PUFA moiety has to
be assessed. The question of the stability and the metabolization
of n-3 lipophenolic structures in biological media have not been fully
explored and additional studies must be performed in future to give
a better understanding of in vitro and in vivo mechanisms of those
PUFA-phenol conjugates, to highlight the role of each part in the
observed activity. Further developments in this ﬁeld should take into
account the increasing amounts of evidence that non enzymatic oxi-
dized polyunsaturated fatty acids (iso-, phyto- and neuroprostanes)
are biologically potent compounds that could be considered to
produce new series of active lipophenols.
Following the same goal, traditional medicinal chemistry ap-
proach should help to design selected linkers (covalent,
hydrolyzable, . . .) between the PUFA and the phenolic part depend-
ing on the way of administration and on the tissue to target.
Appropriate formulations (albumin complex, emulsion, . . .) of such
derivatives will also help to modulate ADME proﬁle and to in-
crease therapeutic index of those new lipophenol derivatives.
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